China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has synthesized tricyclic heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Fudan University has described dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of bone disorders, immunological disorders, inflammatory disorders, viral infections and cancer.
Alicorn Pharmaceutical Co. Ltd. has divulged S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
The discovery of the ‘Warburg effect’ more than 80 years ago implied that inhibiting tumor cells’ ability to consume abnormally large amounts of glucose could prevent them from growing. Taking advantage of the fact that hexokinase-2 catalyzes the first step of glucose metabolism, researchers at Yıldız Teknik Üniversitesi and collaborators identified novel derivatives of the hexokinase-2 inhibitor lonidamine and identified at least one that was potentially more potent and less toxic.
Inventisbio Co. Ltd. and Inventisbio LLC have divulged Werner syndrome helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
